

# 36<sup>th</sup> Annual Meeting Schedule

## Friday, Nov. 12, 2021

7 a.m.–8:30 p.m. Poster and Exhibit Hall

### Presidential Welcome & Awards Ceremony

7:45 – 8:25 a.m.

#### Chair:

Patrick Hwu, MD – *Moffitt Cancer Center*

- 7:45–7:55 a.m. **Presidential Welcome**  
Patrick Hwu, MD – *Moffitt Cancer Center*
- 7:55–8:05 a.m. **Rosenberg Scholar**
- 8:05–8:15 a.m. **Academy of Immuno-Oncology Awards**
- 8:15–8:20 a.m. **Team Science Award**
- 8:20–8:25 a.m. **Lifetime Achievement**

### Session 100: Update Session

8:25–8:55 a.m.

- 8:25–8:40 a.m. **Food and Drug Administration**  
Adnan Jaigirdar, MD, FACS – *Food and Drug Administration*
- 8:40–8:55 a.m. **Food and Drug Administration**  
Marc Theoret, MD – *Food and Drug Administration*

### Session 101: Keynote Address

9:05–9:55 a.m.

#### Chair:

Patrick Hwu, MD – *Moffitt Cancer Center*

- 9:05–9:10 a.m. **Introduction**  
Patrick Hwu, MD – *Moffitt Cancer Center*
- 9:10–9:50 a.m. **Neutralizing Protumor Inflammation: Lessons Learned from Preclinical Mouse Models**  
Lisa M. Coussens, PhD – *Oregon Health & Science University*
- 9:50–9:55 a.m. **Question & Answer**  
Lisa M. Coussens, PhD – *Oregon Health & Science University*

### Break

9:55–10:10 a.m.

### Session 102: Myeloid Cells

10:10 a.m.–12:10 p.m. EST

**Co-Chairs:**

Niroshana Anandasabapathy, MD, PhD – *Weill Cornell Medicine*

Miriam Merad, MD, PhD – *Icahn School of Medicine at Mount Sinai*

10:10–10:15 a.m. **Introduction**

Miriam Merad, MD, PhD – *Icahn School of Medicine at Mount Sinai*

10:15–10:35 a.m. **Myeloid Cells**

Shannon J. Turley, PhD – *Genentech*

10:35–10:55 a.m. **Trem2 in Cancer**

Marco Colonna, MD – *Washington University School of Medicine*

10:55–11:15 a.m. **Tissue-Resident Macrophages: Fueling Early-Stage Lung Cancer**

Maria Casanova-Acebes, PhD – *Icahn School of Medicine at Mount Sinai*

11:15–11:35 a.m. **CD40**

Robert H. Vonderheide, MD, DPhil – *University of Pennsylvania Perelman School of Medicine*

11:35–11:45 a.m. **(676) Altered circulating myeloid states associated with anti-PD-1 resistance induce T cell paralysis in human biliary cancer**

Bridget P. Keenan, MD, PhD – *University of San Francisco*

11:45–11:55 a.m. **(209) Genetically Engineered Myeloid Cells (GEMys) as a Platform to Enhance Antitumor Immunity**

Sabina Kaczanowska, PhD – *National Cancer Institute*

11:55 a.m.–12:05 p.m. **(664) Pulmonary priming of tumor-reactive CD8+ T cells by DC1 is impaired by regulatory T cells**

Maria Zagorulya, BS – *Massachusetts Institute of Technology*

12:05–12:10 p.m. **Closing Remarks**

Niroshana Anandasabapathy, MD, PhD – *Weill Cornell Medicine*

**Session 103: Late-Breaking Abstract Session**

12:10–12:40 p.m. EST

**Chair:**

Margaret K. Callahan, MD, PhD – *Memorial Sloan Kettering Cancer Center*

12:10–12:25 p.m. **Abstract**

12:25–12:40 p.m. **Abstract**

**Lunch and Poster Viewing**

12:40–2:10 p.m.

**Concurrent Rapid Oral Abstract Session 104: Basic Research**

12:55–1:55 p.m. EST

**Co-Chairs:**

Aitziber Buque Martinez, PhD – *Weill Cornell Medical College*

Abigail Overacre-Delgoffe, PhD – *University of Pittsburgh*

12:55–1:03 p.m. **(805) Clonal, activated CD8+ T cells recognizing cardiac alpha-myosin drive immune checkpoint inhibitor associated myocarditis in mice**

Margaret L. Axelrod, BS – *Vanderbilt University*

- 1:03–1:11 p.m. **(700) Increasing MHC-I expression to potentiate immune checkpoint blockade therapy**  
Shengqing Gu, PhD – *Dana-Farber Cancer Institute*
- 1:11–1:19 p.m. **(310) T cell intrinsic DNA damage and repair response as a novel marker associated with clinical response to PD-1 blockade**  
Yuki Muroyama, MD, PhD – *University of Pennsylvania Perelman School of Medicine*
- 1:19–1:25 p.m. **Question and Answer**
- 1:25–1:33 p.m. **(693) Mucosal-Associated Invariant T (MAIT) Cell Regulation Networks in Anti-Tumor Immunity**  
Benjamin Ruf, MD – *National Institutes of Health*
- 1:33–1:41 p.m. **(805) Targeting FPR2 as a novel approach for immunotherapy in pancreatic cancer female patients – Studies of sexual immune dimorphism in the tumor microenvironment**  
Dhifaf Sarhan, PhD – *Karolinska Institutet*
- 1:41–1:49 p.m. **(651) Molecular signature of neoantigen-reactive CD4+ and CD8+ T cells from metastatic human cancers enables prospective antitumor TCR prediction**  
Frank Lowery III, PhD – *National Cancer Institute*
- 1:49–1:55 p.m. **Question and Answer**

#### **Concurrent Rapid Oral Abstract Session 105: Clinical**

12:55–1:55 p.m. EST

##### **Co-Chairs:**

Allison Betof, MD, PhD – *Memorial Sloan Kettering Cancer Center*

Rafah Naqash, MD – *Oklahoma University*

- 12:55–1:03 p.m. **(457) KEYNOTE-495/KeyImPaCT: interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer (NSCLC)**  
Martin Gutierrez, MD – *Hackensack Meridian Health*
- 1:03–1:11 p.m. **(300) Longitudinal plasma proteomic profiling of non-small cell lung cancer patients undergoing immune checkpoint blockade-based therapy**  
Michal Harel, PhD – *Oncohost LTD*
- 1:11–1:19 p.m. **(832) Deep learning reveals predictive sequence concepts within immune repertoires to immunotherapy**  
John-William Sidhom, MD, PhD – *Johns Hopkins University School of Medicine*
- 1:19–1:25 p.m. **Question and Answer**
- 1:25–1:33 p.m. **(503) Clinical Activity of ICT01, an anti-BTN3A-Targeting,  $\gamma$ 9 $\delta$ 2-Activating mAb, Alone and in Combination with Pembrolizumab in Patients with Advanced/Refractory Solid Tumors: EVICTION Trial**  
Martin Wermke – *Uniklinikum Dresden*

1:33–1:41 p.m. **(379) Immune infiltrates are associated with clinical outcomes in patients with resectable soft tissue sarcoma (STS) treated with neoadjuvant immune checkpoint blockade (ICB)**

Emily Z. Keung, MD, MA – *The University of Texas MD Anderson Cancer Center*

1:41–1:49 p.m. **(354) Lenvatinib and pembrolizumab in advanced endometrial carcinoma (EC): long-term efficacy and safety update from a phase 1b/2 study**

Vicky Makker, MD – *Memorial Sloan Kettering Cancer Center*

1:49–1:55 p.m. **Question and Answer**

### **Concurrent Session 106: Exhaustion vs. Stem-like TILs – TILs classification**

2:10–3:25 p.m. EST

#### **Co-Chairs:**

Andrea Schietinger, PhD – *Memorial Sloan Kettering Cancer Center*

Catherine J. Wu, MD – *Dana-Farber Cancer Institute*

2:10–2:35 p.m. **Biomarkers of Exhaustion Guide the Identification of Tumor-Reactive TIL and Peripheral Blood Lymphocytes**

Alena Gros, PhD – *Vall d'Hebron Institute of Oncology*

2:35–3 p.m. **Transcriptional Strategies to Counter T Cell**

Patrick G. Hogan, PhD – *La Jolla Institute for Immunology*

3:00–3:25 p.m. **(Re)modeling Melanoma Tumor Infiltrating Lymphocytes**

Niroshana Anandasabapathy, MD, PhD – *Weill Cornell Medicine*

### **Concurrent Session 107: Re-Imagine Patient Access and Care Delivery in the Era of Digital Medicine**

2:10–3:25 p.m. EST

#### **Co-Chairs:**

Lynda Chin, MD – *Apricity Health LLC*

Patricia Brown, Esq. – *Medically Home Group*

2:10–2:15 p.m. **Precision in Care Delivery and Therapeutic Development in the Era of Digital Medicine**

Sean Khozin, MD MPH – *CancerLinQ*

2:15–2:20 p.m. **Bio/Pharma Perspective**

Rasika Kalamegham – *Genentech Roche*

2:20–2:25 p.m. **Innovation/Startup Perspective**

Patricia Brown, Esq. – *Medically Home Group*

2:25–2:30 p.m. **Overview of the Landscape and Future of Digital Medicine**

Lynda Chin, MD – *Dell Medical School and Apricity Health*

2:30–3:25 p.m. **Panel Discussion**

### **Concurrent Session 108: NK Cells**

2:10–3:25 p.m. EST

#### **Co-Chairs:**

Lewis L. Lanier, PhD – *University of California San Francisco*

Katy Rezvani, MD, PhD – *The University of Texas MD Anderson Cancer Center*

- 2:10–2:15 p.m. **Introduction**  
Katy Rezvani, MD, PhD – *The University of Texas MD Anderson Cancer Center*
- 2:15–2:30 p.m. **Natural Killer Cell Diversity and Activation**  
Lewis L. Lanier, PhD – *University of California San Francisco*
- 2:30–2:45 p.m. **Tumor Infiltrating NK Cells**  
Heidi Cerwenka – *University of Heidelberg*
- 2:45–3 p.m. **Adaptive NK Cells**  
Karl-Johan Malmberg – *Oslo University Hospital*
- 3–3:15 p.m. **CRISPR-edited NK Cells**  
May Daher, MD – *The University of Texas MD Anderson Cancer Center*
- 3:15–3:25 p.m. **(216) Multiplex base editing of NK cell to enhance cancer immunotherapy**  
Minjing Wang, BSc – *University of Minnesota*

**Concurrent Session 109: Biomarkers (Early Trials and Translational Research, Tissue Access Aspects)**

2:10–3:25 p.m. EST

**Co-Chairs:**

Sangeeta Goswami, MD, PhD – *The University of Texas MD Anderson Cancer Center*  
Alessandra Cesano, MD, PhD – *ESSA Pharma Inc.*

- 2:10–2:15 p.m. **Introduction**  
Sangeeta Goswami, MD, PhD – *The University of Texas MD Anderson Cancer Center*
- 2:15–2:33 p.m. **Utility of the Circulating Tumor Genome in Informing Clinical Decisions-Immunotherapy and Combinations**  
Priti S. Hegde, PhD – *Foundation Medicine*
- 2:33–2:51 p.m. **Pronostic and Predictive Value of Tertiary Lymphoid Structures in Human Cancers**  
Catherine Sautes-Fridman, PhD – *Centre de Recherche des Cordeliers*
- 2:51–3:09 p.m. **Host Biomarkers (Microbiome)**  
Christine Spencer, PhD – *Parker Institute for Cancer Immunotherapy*
- 3:09–3:25 p.m. **(76) Spatial mapping of T cell receptors and transcriptomes in renal cell carcinoma following immune checkpoint inhibitor therapy**  
Bryan Iorgulescu, MD – *Dana-Farber Cancer Institute*

**Concurrent Session 110: Microbiome, Metabolism and ER Stress**

2:10–3:25 p.m.

**Co-Chairs:**

Laurie H. Glimcher, MD – *Dana-Farber Cancer Institute*  
Jennifer A. Wargo, MD, MMSc – *The University of Texas MD Anderson Cancer Center*

- 2:10–2:15 p.m. **Overview**  
Jennifer Wargo, MD – *The University of Texas MD Anderson Cancer Center*
- 2:15–2:30 p.m. **ER Stress**  
Juan R. Cubillos-Ruiz, PhD – *Weill Cornell Medicine*
- 2:30–2:45 p.m. **Microbiome**

Wendy Garrett, MD – *Harvard School of Public Health*

2:45–3 p.m. **Metabolic Impact on Tumor Immunity and Therapy**  
Weiping Zou, MD, PhD – *University of Michigan*

3–3:05 p.m. **(839) Microbiota-specific T follicular helper cells drives tertiary lymphoid structure formation and anti-tumor immunity in colorectal cancer**  
Abigail Overacre-Delgoffe, PhD – *University of Pittsburgh*

3:05–3:10 p.m. **(668) Lipid-instructed metabolic rewiring unleash the anti-tumor potential of CD8+ T cells**  
Teresa Manzo, PhD – *IEO*

3:10–3:25 p.m. **Question and Answer**

### Concurrent Session 111: Intratumoral Therapy at a Crossroads

2:10 – 3:25 p.m.

#### Co-Chairs:

Nina Bhardwaj, MD, PhD – *The Tisch Cancer Institute of the Icahn School of Medicine at Mount Sinai*

Adi Diab, MD – *The University of Texas MD Anderson Cancer Center*

2:10–2:15 p.m. **Introduction**  
Nina Bhardwaj, MD, PhD – *The Tisch Cancer Institute of Icahn School of Medicine at Mount Sinai*

2:15–2:25 p.m. **State of the Field and Recent Trials**  
Adi Diab – *The University of Texas MD Anderson Cancer Center*

2:25–2:35 p.m. **Standards for Intratumoral Therapies**  
Aurelien Marabelle, MD, PhD – *Gustave Roussy*

2:35–2:45 p.m. **Endpoints of Efficacy**  
Ignacio Melero, MD, PhD – *FIMA, Clinica Universidad de Navarra*

2:45–2:55 p.m. **Igniting the Fire: Intratumoral Therapy to Turn on Immune Response to cancer**  
Antoni Ribas, MD, PhD – *University of California Los Angeles*

2:55–3:25 p.m. **Panel Discussion**  
Aurelien Marabelle, MD, PhD – *Gustave Roussy*  
Ignacio Melero, MD, PhD – *FIMA, Clinica Universidad de Navarra*  
Antoni Ribas, MD, PhD – *University of California Los Angeles*  
Joshua Brody, MD – *Icahn School of Medicine at Mount Sinai*  
Robert Andtbacka, MD, CM, FACS, FRSC – *Seven and Eight Biopharmaceuticals*  
Stephen Solomon, MD – *Memorial Sloan Kettering Cancer Center*  
Craig L. Slingluff, MD – *University of Virginia School of Medicine*  
Silvia Formenti, MD – *Weill Cornell Medicine*

### Session 112: Debate: Engineered vs. Endogenous T cells

3:25–4:35 p.m. EST

#### Co-Chairs:

Cassian Yee, MD – *The University of Texas MD Anderson Cancer Center*

Alex Marson, MD, PhD – *University of California San Francisco*

3:25–3:40 p.m. **Endogenous T cells**



Cassian Yee, MD – *The University of Texas MD Anderson Cancer Center*

3:40–3:55 p.m. **Targeting Solid Malignancies with “Public” Neoantigen-Specific T Cells**  
Christopher A. Klebanoff, MD – *Memorial Sloan Kettering Cancer Center*

3:55–4:10 p.m. **Reprogramming T cell therapies with CRISPR**  
Alexander Marson, MD, PhD – *University of California San Francisco*

4:10–4:25 p.m. **Engineered T cells – Engineering Next-Generation CAR-T Cells for Cancer**  
Yvonne Chen, PhD – *University of California Los Angeles*

4:25–4:35 p.m. **Panel Debate**  
Alexander Marson, MD, PhD – *University of California San Francisco*  
Cassian Yee, MD – *The University of Texas MD Anderson Cancer Center*  
Yvonne Chen, PhD – *University of California Los Angeles*  
Christopher A. Klebanoff, MD – *Memorial Sloan Kettering Cancer Center*

### Break

4:35–4:50 p.m.

### Session 113: Debate: Declassification/Deconvolution of T cell Types

4:50–6 p.m. EST

#### Co-Chairs

Ira Mellman, PhD – *Genentech*  
Ansuman Satpathy, MD, PhD – *Stanford University School of Medicine*

4:50–4:55 p.m. **Introduction**  
Ansuman Satpathy, MD, PhD – *Stanford University School of Medicine*

4:55–5:05 p.m. **Brief Summary – Exhaustion Side**  
E. John Wherry, PhD – *University of Pennsylvania*

5:05–5:15 p.m. **Brief Summary – Non-Exhausted Side**  
Andrea Schietinger, PhD – *Memorial Sloan Kettering Cancer Center*

5:15–6 p.m. **Panel Debate**  
E. John Wherry, PhD – *University of Pennsylvania*  
Drew M. Pardoll, MD, PhD – *Johns Hopkins University*  
Haydn Kissick, PhD – *Emory University*  
Andrea Schietinger, PhD – *Memorial Sloan Kettering Cancer Center*

### Session 114: Poster Symposium

6:00 –7:00 p.m.

#### Co-Chairs:

Diwakar Davar, MD – *UPMC Hillman Cancer Center*  
Amanda Lund, PhD – *NYU Grossman School of Medicine*

6:00–6:10 p.m. **(30) Blood-based Glycoprotein Signatures in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Receiving First-Line Immune Checkpoint Blockade**  
Klaus Lindpaintner, MD, MPH – *InterVenn*

- 6:10–6:20 p.m.    **(748) Targeting vasoactive intestinal peptide receptor signaling in pancreatic ductal adenocarcinoma for enhanced anti-tumor response to checkpoint blockade**  
Sruthi Ravindranathan, PhD, MS – *Emory University*
- 6:20–6:30 p.m.    **(663) Media based on the metabolic composition of tumor interstitial fluid reveals persistent T cell dysfunction induced through arginine deprivation and exposure to the oncometabolite**  
Yupeng Wang, BS – *University of Pittsburgh*
- 6:30–6:40 p.m.    **(683) Type-I-interferon activates cross-dressed CD11b+ conventional dendritic cells to enhance anti-tumor immunity**  
Ellen Duong, ScB – *Koch Institute*
- 6:40–6:50 p.m.    **(66) Prognostic and predictive value of pre-treatment T-Cell receptors (TCR) repertoire in non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy**  
Afaf Abed, MBBS, FRACP – *Edith Cowan University*
- 6:50–7:00 p.m.    **Question and Answer**
- Poster Reception**  
7–8:30 p.m.



## Saturday, Nov. 13, 2021

### Session 200: SITC Business Meeting

7:15–7:45 a.m.

**Chair:**

Patrick Hwu, MD – *Moffitt Cancer Center*

### Organizer Welcome

8–8:05 a.m.

**Chair:**

Padmanee Sharma, MD, PhD – *The University of Texas MD Anderson Cancer Center*

### Awards Ceremony

8:05–8:20 a.m.

**Chair:**

Leisha A. Emens, MD, PhD – *UPMC Hillman Cancer Center*

8:05–8:10 a.m.                      **Tara Withington Public Service**

8:10–8:15 a.m.                      **Service to JITC Award**

8:15–8:20 a.m.                      **2021 JITC Best Paper**

### Session 201: Update Session

8:20–9:05 a.m.

**Chair:**

Leisha A. Emens, MD, PhD – *UPMC Hillman Cancer Center*

8:20–8:30 a.m.                      **Journal for ImmunoTherapy of Cancer (JITC) Update**  
Pedro J. Romero, MD – *University of Lausanne & University Hospital of Lausanne*

8:30–8:45 a.m.                      **National Cancer Institute (NCI) Update**  
Stephanie L. Goff, MD, FACS – *National Cancer Institute Surgery Branch*

8:45–9:05 a.m.                      **Remembrance of Drs. Martin ‘Mac’ Cheever and Thomas Waldmann**

### Session 202: Richard V. Smalley, MD Memorial Award and Lectureship

9:05–9:55 a.m.

**Chair:**

Patrick Hwu, MD – *Moffitt Cancer Center*

9:05–9:10 a.m.                      **Introduction & 2021 Richard V. Smalley Memorial Award and Lectureship Recognition**  
Patrick Hwu, MD – *Moffitt Cancer Center*

9:10–9:50 a.m.                      **CAR-T Cells for Solid Tumors: Charting a Path Forward**  
Crystal Mackall, MD – *Stanford University*

9:50–9:55 a.m.                      **Question & Answer**  
Crystal Mackall, MD – *Stanford University*

### Break

9:55–10:10 a.m.

### Session 203: COVID Immunobiology/Immunology

10:10 a.m.–noon

#### Co-Chairs:

Nina Bhardwaj, MD, PhD – *The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai*

Kizzmekia Corbett, PhD – *National Institutes of Allergy and Infectious Diseases, NIH*

10:10–10:15 a.m.

#### Opening Remarks

Kizzmekia Corbett, PhD – *National Institutes of Allergy and Infectious Diseases, NIH*

10:15–10:37 a.m.

#### Immune Memory to COVID-19 Infection

Rafi Ahmed, PhD – *Emory University*

10:37–10:59 a.m.

#### Immune responses to SARS-COV2 vaccination in Multiple Myeloma

Samir Parekh, MD – *Mount Sinai School of Medicine*

10:59–11:21 a.m.

#### T-cell Responses to COVID-19

Alessandro Sette, PhD – *La Jolla Institute for Immunology*

11:21–11:38 a.m.

#### (625) COVID-19 vaccination in patients with renal cancer or melanoma receiving immune checkpoint inhibitors

Hannah E. Dzimitrowicz, MD – *Duke Cancer Center*

11:38–11:55 a.m.

#### (626) Dissecting the spatial heterogeneity of SARS-CoV-2-infected tumour microenvironment reveals a lymphocyte-dominant immune response in a HBV-associated HCC patient with COVID-19 history

Mai Chan Lau, PhD – *Institute of Molecular and Cell Biology (IMCB), Agency of Science, Technology and Research (A\*STAR)*

11:55 a.m.–noon

#### Closing Remarks

Nina Bhardwaj, MD, PhD – *The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai*

### Session 204: Late-Breaking Abstract Session

Noon–12:30 p.m.

#### Chair:

Niroshana Anandasabapathy, MD, PhD – *Weill Cornell Medicine*

Noon–12:15 p.m.

#### Abstract

12:15–12:30 p.m.

#### Abstract

### Lunch & Poster Viewing

12:30–2 p.m.

### Concurrent Rapid Oral Abstract Session 205: Basic Research

12:45–1:45 p.m.

#### Co-Chairs:

Kristin G. Anderson, PhD – *Fred Hutchinson Cancer Research Center*

Olivia Rongze Lu, PhD – *University of Texas at Austin, Dell Medical School*

12:45–12:53 p.m.

#### (43) Intravital multiphoton imaging of infiltrating CD8 T cell metabolism during immunotherapy in a murine melanoma model

Alexa R. Heaton, PhD – *Morgridge Institute of Research, University of Wisconsin*

- 12:53–1:01 p.m. **(658) CD8 T cell activation in cancer is comprised of two distinct phases**  
Nataliya Prokhnevskaya, BS – *Emory University*
- 1:01–1:09 p.m. **(660) Targeting T cell fates: converting exhaustion to memory to improve immunotherapeutic responses to cancer**  
Nicole E. Scharping, PhD – *University of California San Diego*
- 1:09–1:15 p.m. **Question and Answer**
- 1:15–1:23 p.m. **(936) Stromal remodeling regulates dendritic cell abundance in the tumor microenvironment**  
Anthanasios Papadas, MD – *University of California San Diego*
- 1:23–1:31 p.m. **(601) Sequencing Immunotherapy Before Lymphatic Ablation Unleashes cDC1-Dependent Antitumor Immunity in HNSCC**  
Robert Saddawi-Konefka, MD, PhD – *University of California San Diego School of Medicine*
- 1:31–1:39 p.m. **(125) Co-opting IL-8 to enhance efficacy of B7H3 CAR T cells against pediatric sarcoma**  
Jessica Lake, MD, MPH – *University of Colorado Anschutz Medical Campus*
- 1:39–1:45 p.m. **Question and Answer**
- Concurrent Rapid Oral Abstract Session 206: Clinical**
- 12:45–1:45 p.m.  
**Co-Chairs:**  
Praveen K. Bommareddy, MS, PhD – *Replimune, Inc.*  
Chris Langsdorf – *Thermo Fisher Scientific*
- 12:45–12:53 p.m. **(493) First-in-human phase 1/2 trial to evaluate the safety and initial clinical activity of DuoBody®-CD40x4-1BB (GEN1042) in patients with advanced solid tumors**  
Melissa L. Johnson, MD – *Sarah Cannon Research Institute*
- 12:53–1:01 p.m. **(350) Phase 2 trial of a DNA vaccine with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)**  
Douglas G. McNeel, MD, PhD – *Carbone Cancer Center, University of Wisconsin*
- 1:01–1:09 p.m. **(449) Concurrent ibrutinib enhances T cell function in patients with chronic lymphocytic leukemia (CLL) treated with lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T cell therapy**  
Jerill Thorpe, MS – *Bristol Myers Squibb*
- 1:09–1:15 p.m. **Question and Answer**
- 1:15–1:23 p.m. **(374) A Phase IB trial of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors**  
Kevin Tyan, BA – *Harvard Medical School*
- 1:23–1:31 p.m. **(529) Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors**  
Eric Van Cutsem, MD, PhD – *University Hospitals Gathiusberg Leuven*
- 1:31–1:39 p.m. **(490) Clinical benefit through Siglec-15 targeting with NC318 antibody in subjects with Siglec-15 positive advanced solid tumors**  
Elaine Shum, MD – *New York University Langone Health*

1:39–1:45 p.m.

## Question and Answer

### Session 207: Presidential Session

2–3:25 p.m.

#### Chair:

Patrick Hwu, MD – *Moffitt Cancer Center*

2:00–2:05 p.m.

#### Introduction

Patrick Hwu, MD – *Moffitt Cancer Center*

2:05–2:20 p.m.

#### (592) ATR-mediated CD47 and PD-L1 upregulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer

Rodney Cheng-En Hsieh, MD – *The University of Texas MD Anderson Cancer Center*

2:20–2:35 p.m.

#### (900) Depleting non-canonical, cell-intrinsic PD-L1 signals induces synthetic lethality to small molecule DNA damage response inhibitors in an immune independent and dependent manner

Anand V. Kornepati – *University of Texas Health Science Center San Antonio*

2:35–2:45 p.m.

#### Expert Discussant

Sandra Demaria, MD – *Weill Cornell Medicine*

2:45–3:00 p.m.

#### (152) Common trajectories of highly effective anti-CD19 chimeric antigen receptor-modified T cells identified by endogenous T cell receptor lineages

Taylor L. Wilson, BS – *St. Jude Children's Research Hospital*

3:00–3:15 p.m.

#### (328) Batf3 dendritic cells and 4-1BB/4-1BB ligand axis are required at the effector phase within the tumor microenvironment for anti-PD-L1 efficacy

Andrea Ziblat, PhD – *University of Chicago*

3:15–3:25 p.m.

#### Expert Discussant

E. John Wherry, PhD – *University of Pennsylvania*

### Break

3:25–3:40 p.m.

### Concurrent Session 208: Locoregional Therapies, Including Radiation, Oncolytic Viruses and Innate Immune Modulators

3:40–4:55 p.m.

#### Co-Chairs:

James W. Welsh, MD – *The University of Texas MD Anderson Cancer Center*

Dimitriy Zamarin, MD, PhD – *Memorial Sloan Kettering Cancer Center*

3:40–4 p.m.

#### Using Low Dose Radiation and Nanoparticles to address PD1 Resistance

James W. Welsh, MD – *The University of Texas MD Anderson Cancer Center*

4–4:20 p.m.

#### Modulation of Anti-Tumor Immunity with Oncolytic Viruses

Dimitriy Zamarin, MD, PhD – *Memorial Sloan Kettering Cancer Center*

4:20–4:30 p.m.

#### Modulators of Tumor Antigenicity by Radiation Therapy

Nils Rudqvist, PhD – *The University of Texas MD Anderson Cancer Center*

- 4:30–4:40 p.m. **(768) Systemic delivery of a tumor-targeted TLR9 agonist conjugate transforms the tumor immune landscape and induces tumor regression in mice**  
Caitlyn Miller, PhD Candidate – *Stanford University*
- 4:40–4:50 p.m. **(758) High-potency synthetic STING agonists rewire the myeloid stroma in the tumour microenvironment to amplify immune checkpoint blockade efficacy in refractory pancreatic ductal adenocarcinoma**  
Akash R. Boda, MS – *The University of Texas MD Anderson Cancer Center*
- 4:50–4:55 p.m. **Questions**

### Concurrent Session 209: Single Cell Approaches to Advancing Understanding of Immunotherapy Resistance

- 3:40–4:55 p.m.  
**Co-Chairs:**  
Kellie N. Smith, PhD – *Johns Hopkins School of Medicine*  
Daniel K. Wells, PhD – *Parker Institute for Cancer Immunotherapy*

- 3:40–3:45 p.m. **Introduction**  
Kellie N. Smith, PhD – *Johns Hopkins School of Medicine*
- 3:45–4:10 p.m. **Keynote**  
Ansuman Satpathy, MD, PhD – *Stanford University School of Medicine*
- 4:10–4:20 p.m. **Longitudinal Single Cell Genomics Reveals Mechanisms of Resistance to Combination Immune Checkpoint Blockade**  
Alexander Huang, MD – *University of Pennsylvania*
- 4:20–4:30 p.m. **Increased Post-Infusion CD57+ CD19-CAR T Cells in Patients with Durable Remission**  
Zinaida Good – *Stanford University*
- 4:30–4:40 p.m. **Epigenomic Features of Exhausted T-cells During Immunotherapy**  
Debattama Sen, PhD – *Massachusetts General*
- 4:40–4:50 p.m. **(655) Landscape of helper and regulatory CD4+ T cells in melanoma**  
Giacomo Oliveira, PhD – *Dana-Farber Cancer Institute*
- 4:50–4:55 p.m. **Closing Remarks**  
Daniel K. Wells, PhD – *Parker Institute of Cancer Immunotherapy*

### Concurrent Session 210: Novel Targets, Resistance Mechanisms

- 3:40–4:55 p.m.  
**Co-Chairs:**  
Jason J. Luke, MD, FACP – *UMPC*  
Irving L. Weissman, MD – *Stanford University*
- 3:40–3:55 p.m. **Targeting Glycobiology as a Therapeutic Approach in Cancer Immunotherapy**  
Carolyn Bertozzi, PhD – *Stanford University*
- 3:55–4:10 p.m. **Normal and Neoplastic Stem Cells**  
Irving L. Weissman, MD – *Stanford University*
- 4:10–4:25 p.m. **Moving Beyond First Generation STING Agonist Approaches**  
Jason J. Luke, MD, FACP – *UPMC Hillman Cancer Center*

4:25–4:40 p.m. **Flanking Solid Tumors via Immune-Mediated Disruption of Desmoplastic Stroma**  
Ellen Pure, PhD – *University of Pennsylvania*

4:40–4:55 p.m. **(261) A functional genetic screen uncovers regulators of intratumoral macrophage function and reveals CD24 as a novel target for cancer immunotherapy by macrophages**  
Amira Barkal, MD, PhD – *Brigham & Women's Hospital*

### Concurrent Session 211: Team Science to Catalyze Advancements in Research

3:40–4:55 p.m.

#### Co-Chairs:

Luis A. Diaz, MD – *Memorial Sloan Kettering Cancer Center*

Mark Stewart, PhD – *Friends of Cancer Research*

3:40–3:55 p.m. **TMB – Pro**  
Luc Morris, MD – *Memorial Sloan Kettering Cancer Center*

3:55–4:10 p.m. **High TMB Fails to Predict Immune Checkpoint Blockade Response in All Cancer Types**  
Daniel J. McGrail, PhD – *The University of Texas MD Anderson Cancer Center*

4:10–4:25 p.m. **KN158 TMB Data**  
Aurelien Marabelle, MD, PhD – *Gustave Roussy*

4:25–4:40 p.m. **Diagnostic Perspective**  
Yardena Samuels, PhD – *Weizmann Institute of Science*

4:40–4:55 p.m. **Panel Discussion**  
Aurelien Marabelle, MD, PhD – *Gustave Roussy*  
Daniel J. McGrail, PhD – *The University of Texas MD Anderson Cancer Center*  
Luc Morris, MD – *Memorial Sloan Kettering Cancer Center*  
Eric Rubin, MD – *Merck*  
Yardena Samuels, PhD – *Weizmann Institute of Science*

### Concurrent Session 212: Cellular Therapies

3:40–4:55 p.m.

#### Co-Chairs:

Michel Sadelain, MD, PhD – *Memorial Sloan Kettering Cancer Center*

Philip D. Greenberg, MD – *Fred Hutchinson Cancer Center*

3:40–3:55 p.m. **(561) Triple checkpoint blockade, but not anti-PD1 alone, enhances the efficacy of engineered adoptive T cell therapy in advanced ovarian cancer**  
Kristin G. Anderson, PhD – *Fred Hutchinson Cancer Center*

3:55–4:10 p.m. **(578) CD8-targeted IL-2 drives potent anti-tumor efficacy and promotes action of tumor specific vaccines**  
Robert D. Schreiber, PhD – *Washington University School of Medicine*

4:10–4:25 p.m. **(117) FT536 Path to IND: Ubiquitous targeting of solid tumors with an off-the-shelf, first-of-kind MICA/B-specific CAR-iNK cellular immunotherapy**  
Bryan Hancock, PhD – *Fate Therapeutic, Inc.*

4:25–4:40 p.m. **(221) CRISPR screen identifies loss of IFN $\gamma$ R signaling and downstream adhesion as a resistance mechanism to CAR T-cell cytotoxicity in solid but not liquid tumors**  
Rebecca C. Larson, BS – *Jounce Therapeutics*



4:40–4:55 p.m.

**(132) HLA-independent T cell receptors effectively target low abundance antigens**  
Jorge Mansilla-Soto, PhD – *Memorial Sloan Kettering Cancer Center*

**Concurrent Session 213: A Multidisciplinary Approach to Neoadjuvant, Intralesional, and Cell-based Immunotherapy**

3:40 – 4:55 p.m.

**Co-Chairs:**

Genevieve Boland, MD, PhD – *Massachusetts General Hospital*

Kelly Olino, MD, FACS – *Yale School of Medicine*

3:40–3:55 p.m.

**Neoadjuvant Immunotherapy in Sarcoma**

Christina Roland, MD – *The University of Texas MD Anderson Cancer Center*

3:55–4:15 p.m.

**Intralesional Treatment in Head and Neck Cancer**

Sara Pai, MD, PhD – *Massachusetts General Hospital/Harvard*

4:15–4:30 p.m.

**T-cell Based Immunotherapy for Metastatic Breast Cancer**

Stephanie L. Goff, MD, FACS – *National Cancer Institute Surgery Branch*

4:30–4:40 p.m.

**(492) Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-naïve patients with advanced cancers**

David O'Malley – *OSU Medical Center*

4:40–4:50 p.m.

**(337) Intratumoral immune therapy for recurrent breast cancer with polyICLC, and tremelimumab combined with systemic durvalumab**

Craig Slingluff, MD – *University of Virginia*

4:50–4:55 p.m.

**Closing Remarks**

**Break**

4:55–5:10 p.m.

**Concurrent Session 214: Radiomics & Imaging**

5:10–6:25 p.m.

**Co-Chairs:**

Neeta Pandit-Taskar, MD – *Memorial Sloan Kettering Cancer Center*

Ian A. Wilson, PhD – *ImaginAb Inc.*

5:10–5:35 p.m.

**CT Radiomics in Immuno-Oncology Clinical Development for Lung Cancer**

Qin Li, PhD -- *AstraZeneca*

5:35–6:00 p.m.

**Emerging Technologies to Image Immune Cell Changes in Response to Therapy**

Elisabeth De Vries – *University of Groningen*

6:00–6:25 p.m.

**Cell Labelling Methods to Track Immune Cells**

Peter Choyke, MD – *National Institutes of Health*

**Concurrent Session 215: Clinical Considerations in Toxicity Management and Survivorship**

5:10–6:25 p.m.

**Co-Chairs:**

Marc S. Ernstoff, MD – *National Institute of Health*  
Mary-Kate Kasler – *Memorial Sloan Kettering Cancer Center*

- 5:10–5:30 p.m. **Clinical Considerations for Immune Checkpoint Inhibitor Toxicity Management and Survivorship**  
Marianne Davies, DNP, AOCNP – *Yale School of Nursing*
- 5:30–5:50 p.m. **Survivorship & Toxicity Management – Physician Perspective**  
Jarushka Naidoo, MBBCH, MHS – *Beaumont Hospital Dublin*
- 5:50–6 p.m. **(234) Distinct efficacy and immunological responses to  $\alpha$ PD-1,  $\alpha$ PD-L1 and  $\alpha$ PD-L2 immunotherapy in aged versus young hosts**  
Myrna G. Garcia, BS – *UTHSA*
- 6–6:10 p.m. **(806) PD-1 blockade affects inflammation and metabolic flexibility to potentially mediate cardiac immune-related adverse events**  
Steven M. Bronson, DVM – *Wake Forest School of Medicine*
- 6:10–6:20 p.m. **(814) Cutaneous Immune-related Adverse Events are Protective of Mortality in Patients Treated with anti-PD1 and anti-PDL1 therapy in a multi-institutional cohort study**  
Yevgeniy R. Semenov, MD – *Massachusetts General Hospital, Harvard Medical School*
- 6:20–6:25 p.m. **Expert Discussant**  
Igor Puzanov, MD, MSCI, FACP – *Roswell Park Comprehensive Cancer Center*

#### Concurrent Session 216: Exosomes and Cellular Engineering

5:10–6:25 p.m.  
**Co-Chairs:**  
Sriram Sathyanarayanan, PhD – *Codiak BioScience*  
Helen E. Heslop, MD – *Baylor College of Medicine*

- 5:10–5:30 p.m. **Towards Tumor-Specificity: Engineering CAR T cells to Target the Tn-glycopeptidome**  
Avery D. Posey, PhD – *University of Pennsylvania School of Medicine*
- 5:30–5:50 p.m. **Next-Generation Approaches**  
Marcela V. Maus, MD, PhD – *Massachusetts General Hospital*
- 5:50–6:10 p.m. **Developing Engineered Exosome Based Therapeutics for Immuno-Oncology**  
Sriram Sathyanarayanan, PhD – *Codiak Biosciences*
- 6:10–6:25 p.m. **(130) Engineered natural killer cells reactively block TIGIT and CD73 in the GBM microenvironment**  
Kyle B. Lupo, BS – *Purdue University*

#### Concurrent Session 217: Neoadjuvant Therapies

5:10–6:25 p.m.  
**Co-Chairs:**  
Christian U. Blank, MD – *The Netherlands Cancer Institute*  
Tina Cascone, MD, PhD – *The University of Texas MD Anderson Cancer Center*

- 5:10–5:30 p.m. **B cells/TLS**  
Tullia C. Bruno, PhD – *University of Pittsburgh*

5:30-5:50 p.m.

**Neoadjuvant in Melanoma: The Perfect Model**

Georgina Long, MBBS, PhD, BSc, FRAC – *The University of Sydney*

5:50-6:10 p.m.

**Immune Repertoire T cell Overview in Neoadjuvant Immunotherapy**

Kellie N. Smith, PhD – *Johns Hopkins School of Medicine*

6:10 – 6:25 p.m.

**Panel Discussion**

Tullia C. Bruno, PhD – *University of Pittsburgh*

Georgina Long, MBBS, PhD, BSc, FRAC – *The University of Sydney*

Kellie N. Smith, PhD – *Johns Hopkins School of Medicine*

**Concurrent Session 218: Immune Checkpoints – New Indications, Mechanisms, and Controversies**

5:10-6:25 p.m.

**Co-Chairs:**

Piers J. Ingram, PhD – *Hummingbird Bioscience Pte Ltd*

Paolo A. Ascierto, MD – *Istituto Nazionale Tumori IRCCS Fondazione G. Pascale*

5:10-5:30 p.m.

**VISTA: a promising target for cancer immunotherapy**

Piers J. Ingram, PhD – *Hummingbird Bioscience Pte Ltd*

5:30-5:50 p.m.

**Adenosine pathway as new possible target for immunotherapy**

John Stagg, PhD – *CHUM Research Centre*

5:50-6:10 p.m.

**Is Anti-LAG-3 the Next Effective Immunotherapy Treatment? Certainties and Controversies**

Paolo A. Ascierto, MD – *Istituto Nazionale Tumori IRCCS Fondazione G. Pascale*

6:10-6:25 p.m.

**(270) Anti-CD47 immunotherapy as a therapeutic strategy for the treatment of breast cancer brain metastasis**

Jessica D. Mackert, PhD – *Wake Forest University*

**Award Ceremony**

6:30-7 p.m.

**Poster Reception**

7-8:30 p.m.

**The CheckPoints Party**

8:30-11:30 p.m.

## Sunday, Nov. 14, 2021

### Organizer Welcome

8–8:05 a.m.

#### Chair:

Paolo A. Ascierto, MD – *Istituto Nazionale Tumori IRCCS Fondazione G. Pascale*

### Medal of Honor and Project Lightspeed

8:05–8:30 a.m.

#### Chair:

Patrick Hwu, MD – *Moffitt Cancer Center*

8:05–8:10 a.m. **Introduction**

Patrick Hwu, MD – *Moffitt Cancer Center*

8:10–8:30 a.m. **Project Lightspeed**

Ugur Sahin, MD – *BioNTech*

Özlem Türeci, MD – *BioNTech*

### Session 300: Novel Bispecifics

8:30–10:30 a.m.

#### Co-Chairs:

Ann F. Cheung, PhD – *Dragonfly Therapeutics, Inc.*

Dimitris Skokos, PhD – *Regeneron Pharmaceuticals, Inc.*

8:30–8:52 a.m. **Human Costimulatory Bispecific Antibodies in Cancer Immunotherapy: Focus in Solid Tumors**

Dimitris Skokos, PhD – *Regeneron Pharmaceuticals, Inc.*

8:52–9:15 a.m. **From Classical Antibody to Novel Multispecific Biologics: Applications to T and NK cell Engagers**

Marielle Chiron Cluster – *Sanofi*

9:15–9:37 a.m. **Tetravalent Bispecifics: Next Generation Cancer Therapy to Overcome Immune Evasion**

Michelle Morrow, PhD – *F-star Therapeutics*

9:37–10 a.m. **Mobilizing the Immune System with Bispecific Antibodies and Engineered Cytokines**

John R. Desjarlais, PhD – *Xencor, Inc.*

10–10:30 a.m. **Lessons learned and forward-looking perspectives on bi-/multi-specifics**

Dimitris Skokos, PhD – *Regeneron Pharmaceuticals, Inc.*

Marielle Chiron Cluster – *Sanofi*

Michelle Morrow, PhD – *F-star Therapeutics*

John R. Desjarlais, PhD – *Xencor, Inc.*

### Break

10:30–10:45 a.m.

### Concurrent Session 301: Hot Topic Symposium: RNA Vaccines: from COVID back to Cancer

10:45–12:15 p.m.

#### Co-Chairs:

Ugur Sahin, MD – *BioNTech SE*

Tal Zaks, MD, PhD – *Moderna*

10:45–11 a.m.	Robert S. Meehan, MD – <i>Moderna</i>
11–11:15 a.m.	TBA
11:15–11:30 a.m.	Catherine J. Wu, MD – <i>Dana-Farber Cancer Institute</i>
11:30–11:45 a.m.	Noam Solomon, PhD – <i>Immunai</i>
11:45 a.m.–12:15 p.m.	<b>Panel Discussion</b> Ugur Sahin, MD – <i>BioNTech</i> Tal Zaks, MD, PhD Robert S. Meehan, MD – <i>Moderna</i> Catherine J. Wu, MD – <i>Dana-Farber Cancer Institute</i> Noam Solomon, PhD – <i>Immunai</i>

### Concurrent Session 302: Hot Topic Symposium: ODAC and Accelerated Approvals

10:45 – 12:15 p.m.

#### Co-Chairs:

Alessandra Cesano, MD, PhD – *ESSA Pharma Inc.*

Daniel S. Chen, MD, PhD

Leisha A. Emens, MD, PhD – *UPMC Hillman Cancer Center*

10:45-10:50 a.m.	<b>Introduction</b> Leisha A. Emens, MD, PhD – <i>UPMC Hillman Cancer Center</i>
10:50-11:05 a.m.	<b>FDA</b> Gautam Mehta, MD – <i>Food and Drug Administration</i>
11:05-11:20 a.m.	<b>Clinical/ODAC Member</b> David F. McDermott, MD – <i>Beth Israel Deaconess Medical Center</i>
11:20-11:35 a.m.	<b>Biostatistics</b> Elizabeth Garrett-Mayer, PhD – <i>American Society of Clinical Oncology</i>
11:35-11:50 a.m.	<b>Pharma Regulatory Affairs</b> Scot Ebbinghaus, MD – <i>Merck</i>
11:50 a.m.-12:15 p.m.	<b>Panel Discussion</b> Alessandra Cesano, MD, PhD – <i>ESSA Pharma Inc.</i> Daniel S. Chen, MD, PhD Leisha A. Emens, MD, PhD – <i>UPMC Hillman Cancer Center</i> Scot Ebbinghaus, MD – <i>Merck</i> Elizabeth Garrett-Mayer, PhD – <i>American Society of Clinical Oncology</i> David F. McDermott, MD – <i>Beth Israel Deaconess Medical Center</i> Gautam Mehta, MD – <i>Food and Drug Administration</i>

#### Break

12:15–12:45 p.m.

### Session 303: Coronavirus, Cancer, and Immunotherapy: Navigating Clinical Trials and Treatment

12:45–2:45 p.m.

**Co-Chair:**

Margaret K. Callahan, MD, PhD – *Memorial Sloan Kettering Cancer Center*  
Samit Hirawat, MD – *Bristol Myers Squibb*

12:45–12:50  
p.m.

**Introduction**

Margaret K. Callahan, MD, PhD – *Memorial Sloan Kettering Cancer Center*

12:50–1:15  
p.m.

**Coronavirus, Cancer, and Immunotherapy: Navigating Clinical Trials and Treatment - Clinician Perspective**

Jeffrey Weber, MD, PhD – *NYU Langone Medical Center*

1:15–1:40 p.m.

**Perspectives on Virtual Clinical Trials - A New Normal post-COVID**

Kannan Natarajan, PhD – *Pfizer*

1:40–2:05 p.m.

**FDA Perspective: Cancer Clinical Trials During the Covid-19 Pandemic**

Lorraine Pelosof, MD, PhD – *Food and Drug Administration*

2:05–2:45 p.m.

**Impact of COVID on Clinical Trials and their Conduct**

Kannan Natarajan, PhD – *Pfizer*

Lorraine Pelosof, MD, PhD – *Food and Drug Administration*

Jeffrey Weber, MD, PhD – *NYU Langone Medical Center*

**Break**

2:45–3 p.m.

**Session 304: Phase-Dependent Regulatory Considerations in Manufacturing of Cellular Therapy Products**

3 p.m. – 4:30 p.m.

**Co-Chairs:**

Emily Hopewell, PhD – *Indiana University*

Alessandra Cesano, MD, PhD – *ESSA Pharma, Inc.*

Cecila Yeung, MD – *Fred Hutchinson Cancer Research Center*

Raj K. Puri, MD, PhD – *Food and Drug Administration*

3–3:20 p.m.

**FDA - Phase-dependent regulatory considerations for potency assays of unmodified and/or gene-modified cell therapy products**

Kimberly Schultz, PhD – *Food and Drug Administration*

3:20–3:40 p.m.

**Regulatory Considerations for Late-Stage Manufacturing of Cellular and Gene Therapy Products**

Matthew Klinker, PhD – *Food and Drug Administration*

3:40–3:55 p.m.

**Transformation of potency/manufacturing throughout development – Gene Modified**

Sugu Patro – *Kite, A Gilead Company*

3:55–4:10 p.m.

**Transformation of potency/manufacturing throughout development – Unmodified agents**

Robert Pierce, MD – *Sensei Therapeutics*

4:10–4:30 p.m.

**Panel Discussion**

Kimberly Schultz, PhD – *Food and Drug Administration*

Matthew Klinker, PhD – *Food and Drug Administration*

Sugu Patro – *Kite, A Gilead Company*

Robert Pierce, MD – *Sensei Therapeutics*